Caribou Biosciences Overview

  • Founded
  • 2011
Founded
  • Status
  • Public
  • Employees
  • 76
Employees
  • Stock Symbol
  • CRBU
Stock Symbol
  • Share Price
  • $9.49
  • (As of Thursday Closing)

Caribou Biosciences General Information

Description

Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 2929 7th Street
  • Suite 105
  • Berkeley, CA 94710
  • United States
+1 (510) 000-0000

Caribou Biosciences Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Caribou Biosciences Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$9.49 $8.85 $8.37 - $32.65 $536M 60.6M 548K -$3.00

Caribou Biosciences Financials Summary

In Thousands,
USD
TTM 30-Sep-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 1,452,130
Revenue 8,023 12,361 5,788
EBITDA (62,707) (35,443) (31,260)
Net Income (63,147) (34,308) (23,431)
Total Assets 461,960 36,046 61,933
Total Debt 0 1,578 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Caribou Biosciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Caribou Biosciences‘s full profile, request access.

Request a free trial

Caribou Biosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Caribou Biosciences‘s full profile, request access.

Request a free trial

Caribou Biosciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients wi
Biotechnology
Berkeley, CA
76 As of 2021
00000
0000 0000-00-00
00000000 00000

00000 00

or in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint o
0000 000000000
Cambridge, MA
00 As of 0000
00000
0000 0000-00-00
00000000000 00000

0000000

velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, s
0000000000000
Beijing, China
000 As of 0000
00000
0000 0000-00-00
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Caribou Biosciences Competitors (49)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Arbor Biotechnologies Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
0000000 Venture Capital-Backed Beijing, China 000 00000 00000000000 00000
0000000 0000000000 Formerly VC-backed Brisbane, CA 000 0000 00000000 0000
000000000 Venture Capital-Backed San Diego, CA 00 00000 00000000000 00000
000000 0000000 Venture Capital-Backed Menlo Park, CA 00 000.00 000000000 - 000.00
You’re viewing 5 of 49 competitors. Get the full list »

Caribou Biosciences Patents

Caribou Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3749338-A1 Humanized bcma antibody and bcma-car-t cells Pending 16-Jan-2019 00000000000
US-20210155704-A1 Humanized bcma antibody and bcma-car-t cells Granted 16-Jan-2019 00000000000
US-20200399387-A1 Humanized bcma antibody and bcma-car-t cells Granted 16-Jan-2019 00000000000
US-10927182-B2 Humanized bcma antibody and bcma-car-t cells Active 16-Jan-2019 00000000000 0
US-11021542-B1 Humanized bcma antibody and bcma-car-t cells Active 16-Jan-2019 C07K16/2878 0
To view Caribou Biosciences’s complete patent history, request access »

Caribou Biosciences Executive Team (16)

Name Title Board Seat Contact Info
Rachel Haurwitz Ph.D Chief Executive Officer & Founder
Jason O'Byrne Chief Financial Officer
Barbara McClung JD Secretary, Administration & Chief Legal Officer, Legal
Steven Kanner Ph.D Chief Scientific Officer
Ruhi Khan Executive
You’re viewing 5 of 16 executive team members. Get the full list »

Caribou Biosciences Board Members (11)

Name Representing Role Since
Andrew Guggenhime Self Board Member 000 0000
Nancy Whiting Caribou Biosciences Board Member 000 0000
Natalie Sacks MD Self Board Member 000 0000
Philip Austin Anterra Capital Board Member 000 0000
Robert Weisskoff Ph.D Self Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Caribou Biosciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Caribou Biosciences Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Caribou Biosciences‘s full profile, request access.

Request a free trial